Zheng Quan Zhi Xing·2025-06-18 09:27Group 1 - The issuer of the convertible bonds is Yifeng Pharmacy Chain Co., Ltd., with a total issuance amount of RMB 1,797.43 million, net proceeds after issuance costs amounting to RMB 1,780.26 million [2][3][14] - The bonds have a maturity period of six years, from March 4, 2024, to March 3, 2030, with a face value of RMB 100 per bond [3][4] - The coupon rates for the bonds are set at 0.30% for the first year, 0.50% for the second year, and 1.00% for the third year [4][5] Group 2 - The initial conversion price for the bonds is set at RMB 39.85 per share, subject to adjustments based on various corporate actions [5][6] - The conversion price will be adjusted to RMB 32.79 per share effective from June 7, 2024, due to the company's annual profit distribution [7][8] - Further adjustments will reduce the conversion price to RMB 32.54 per share effective from October 15, 2024, and to RMB 32.14 per share effective from June 18, 2025 [8][19] Group 3 - The total amount raised from the bond issuance will be used for projects including the construction of pharmaceutical warehouses in Jiangsu, Hubei, and Hebei, with a total investment of RMB 2,534.33 million [14][15] - The bonds are rated AA by a credit rating agency, with a stable outlook, and the issuer's credit rating is also maintained at AA [16][17] - The bonds will not be secured, and the management of the raised funds will be conducted in a designated special account [15][16] Group 4 - The actual controller and major shareholders have reduced their holdings of the convertible bonds, with a total of 5,259,730 bonds sold, representing 29.26% of the total issuance [20][21] - The company has also repurchased and canceled a portion of restricted stock from its 2022 incentive plan, which does not affect the conversion price of the bonds [21][22] - The company will continue to monitor the impact of these actions on its operational performance and debt repayment capabilities [22]